Our focus is on discovery and early clinical development of treatments for well-defined patient populations suggesting relevant commercial opportunities. We aim to retain ownership of product candidates through to proof of concept after which we expect to partner with established pharma companies for late-stage development and commercialisation.
US28 is a novel CMV-specific target
INNOVATION IN TARGETING CMV VIRUS
Leveraging the active function of US28 to gain access to CMV infected cells
Membrane protein encoded by the virus
Exclusively expressed on virus infected cells
Expressed during both lytic and latent phase
Continuously internalizing
Acts as a chemokine scavenger
Our patented SYN002 drug candidate
SAFE AND TARGETED
SELECTIVELY kills infected cells, without impacting organ function